A new study highlights the Cardio-Ankle Vascular Index (CAVI) as a powerful tool for predicting COPD progression and outcomes ...

The US Food and Drug Administration (FDA) has approved mepolizumab as a maintenance treatment for chronic obstructive ...

GSK has gained approval from the US Food and Drug Administration (FDA) for its monoclonal antibody, Nucala (mepolizumab), as ...

New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of ...

A BMJ Open Respiratory Research study finds women aged over 40 face a 50% higher risk of developing COPD than men—even non-smokers. Indoor pollutants (cooking fumes, cleaning sprays), occupational ...

Current recommendations for diagnosis of COPD in patients with respiratory symptoms require detection of airflow obstruction ...

The GOLD classification is used to determine COPD severity and help form a treatment plan. This is based on the spirometry test result of your FEV1. This is the amount of air you can breathe out ...

London: GSK plc has received approval from the US Food and Drug Administration (FDA) for Nucala (mepolizumab) as an add-on ...

GSK’s Nucala receives US FDA approval for use in adults with chronic obstructive pulmonary disease: London, UK Saturday, May 24, 2025, 11:00 Hrs [IST] GSK plc announced that the ...

Field sobriety tests are commonly used by law enforcement to assess a driver's level of impairment. Certain factors can ...

The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis and ...

The FDA has granted approval to GSK's Nucala as an add-on maintenance treatment for adult patients suffering from inadequately controlled COPD.